Idarubicin Hydrochloride is the hydrochloride salt of Idarubicin, an anthracycline antibiotic and daunomycin analog with antimicrobial and anti-cancer antileukemic properties. It is a Topoisomerase II inhibitor, interfering with DNA replication and RNA transcription. The compound was developed by Johnson & Johnson. Idarubicin is metabolished into Idarubicinol (a 13-dihydro derivative) which is more stable than the parent form and just as active in in vitro models. The product is used in apoptosis research. Idarubicin Hydrochloride is soluble in DMSO.